期刊文献+

湖北某院2017-2020年抗抑郁药物的临床应用分析 被引量:1

Analysis of the Clinical Application of Antidepressants in a Hospital of Hubei from 2017 to 2020
下载PDF
导出
摘要 目的:分析抗抑郁药的临床应用情况及发展趋势,为抗抑郁药物的临床用药和患者合理选药提供参考和依据。方法:对2017-2020年十堰市太和医院抗抑郁药的用药品种、销售金额、用药频度(defined daily doses,DDDs)、日均费用(defined daily dose cost,DDC)、年均增长率(average annual rate of growth,AARG)及药物应用指数(drug utilization index,DUI)进行统计和分析。结果:我院传统抗抑郁药有2个品种,新型抗抑郁药有10个品种。2017-2020年抗抑郁药的销售金额和用药频度逐年增长,年均增长率为16.54%;艾司西酞普兰、舍曲林和曲唑酮4年中用药频度排序始终保持在前3位;新型抗抑郁药的DDC明显高于传统抗抑郁药,新型抗抑郁药的药物DUI远小于1,传统抗抑郁药的药物DUI大于1。结论:抗抑郁药临床应用呈逐年增长趋势;通过提高合理用药水平,降低新型抗抑郁药的DDC,可以让更多患者获益。 Objective To analyze the clinical application and development trend of antidepressants,so as to provide basis and reference for clinical use of antidepressants and rational drug selection for patients.Methods From 2017 to 2020,the types of antidepressants,sales amount,defined daily doses(DDDs),defined daily dose cost(DDC),average annual rate of growth(AARG)and drug utilization index(DUI)in Shiyan Taihe Hospital were statistically analyzed.Results There are 2 kinds of traditional antidepressants and 10 kinds of new antidepressants in our hospital.The consumption sum and DDDs of antidepressants increased year by year from 2017 to 2020,with AARG of 16.54%.The DDDs of Escitalopram,Sertraline and Trazodone remained in the top three in the past four years.The DDC of new antidepressants was significantly higher than that of traditional antidepressants.The DUI of new antidepressant is far less than 1,and the DUI of traditional antidepressant is greater than 1.Conclusion The clinical use of antidepressants is increasing year by year.By improving the level of rational drug use and reducing the DDC of new antidepressants,more patients can benefit.
作者 兰鸿 陈鸿梅 曾顺 钟萍 LAN Hong;CHEN Hong-mei;ZENG Shun;ZHONG Ping(Department of Pharmacy,Taihe Hospital;Mental Health Center of Taihe Hospital;Institute of Basic Medical Sciences,Hubei University of Medicine,Shiyan,Hubei 442000,China)
出处 《湖北医药学院学报》 CAS 2022年第2期159-163,共5页 Journal of Hubei University of Medicine
基金 十堰市太和医院2019年院级基金项目(2019JJXM099)。
关键词 抗抑郁 药物 用药频度 日均费用 年均增长率 药物应用指数 Anti-depression Drug Defined daily doses Defined daily dose cost Average annual rate of growth Drug utilization index
  • 相关文献

参考文献8

二级参考文献60

  • 1张美玲,薛飞.2000年~2003年杭州地区21家医院抗抑郁药利用分析[J].中国药房,2005,16(4):281-282. 被引量:9
  • 2黄静,任榕娜.丙戊酸药物的肝毒性研究进展[J].医学综述,2006,12(8):492-494. 被引量:5
  • 3王晓鹏,吴丽玲,王维平.传统抗癫痫药物对认知功能影响的研究进展[J].脑与神经疾病杂志,2007,15(2):148-149. 被引量:5
  • 4French JA,Pedley TA.Initial management of epilepsy[J].N Engl J Med,2008,359(2):166-76.
  • 5Dieter S.Drug treatment of epilepsy:Options and limitations[J].Epilepsy&Behavior,2009,15(1):56-65.
  • 6Kwan P,Brodie MJ.Early identification of refractory epilepsy[J].N Engl J Med,2000,342(5):314-319.
  • 7Arroyo S,Dodson WE,Privitera MD,et al.Randomized dose-controlled study of topiramate as first-line therapy in epilepsy[J].Acta Neurol Scand 2005,112(4):214-222.
  • 8French JA,Kanner AM,Bautista J,et al.Efficacy and tolerability of the new antiepileptic drugs Ⅰ:treatment of new onset epilepsy:report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society[J].Neurology,2004,62(8):1252-60.
  • 9French JA,Kanner AM,Bautista J,et al.Efficacy and tolerability of the new antiepileptic drugs Ⅱ:treatment of refractory epilepsy:report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society[J].Neurology,2004,62(8):1261-73.
  • 10Pratoomsri W,Yatham LN,Bond DJ,et al.Oxcarbazepine in the treatment of bipolar disorder:a review[J].Can J Psychiatry,2006,51(8):540-545.

共引文献234

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部